Skip to content

Inspection prep notes · Quality system

Quality unit responsibilities and authority

Also called: quality unit, quality control unit, QU, QCU

FDA looks less at whether a quality unit exists on the organization chart than at whether it actually and independently reviewed records, handled investigations, made release decisions and oversaw contractors. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1The quality unit's responsibilities and procedures were not established in writing

For example, at the time of the inspection, written procedures describing the responsibilities of the quality unit had not been established …

FDA Warning Letter · R3 Medical Companies · 2026-08-25 · View document

Your firm failed to establish written procedures that define the roles, responsibilities, and procedures of quality unit personnel.

FDA 483 · Conroe Welding Supply, Inc · 2026-10-23 · View document

2Testing and release approval were done by the same person, with no independent check

The Quality Control Manager performs and approves all laboratory tests without independent review. The testing and batch release approval executed by the same individual, which represents a lack of segregation of duties in the quality control process.

FDA 483 · SURETEC INNOVATIONS LLC · 2026-10-23 · View document

It was observed on batch records that the filler, tester, and product release approver were the same person, demonstrating a lack of independent verification and segregation of duties …

FDA 483 · Conroe Welding Supply, Inc · 2026-10-23 · View document

3The quality unit did not make sure production records were complete and free of errors

For example, your QU failed to ensure appropriate batch-production records with complete details.

FDA Warning Letter · Zhejiang Gaorong Cosmetic Co., Ltd. · 2026-10-20

Your quality unit does not review production records adequately to ensure there are no errors that have occurred.

FDA 483 · Andelyn Biosciences, Inc. · 2026-10-30 · View document

4The quality unit did not thoroughly investigate out-of-specification results

Despite the ongoing investigation, your quality unit (QU) released the batch on (b)(4) , and subsequently shipped the batch for the U.S. market on (b)(4) , after your firm retested the sample and obtained passing results.

FDA Warning Letter · VeganicSKN Limited · 2026-09-29 · View document

A d tailed review of the investigation revealed that the Quality Unit did not thoroughly assess the potential root causes of these high microbial counts. In Phase 1, your quality unit ruled out laboratory errors, stating that “everything was correct from the (contract) lab”.

FDA 483 · VitaCare Labs Inc. · 2026-10-23 · View document

5Quality oversight of contractors was not performed or not defined in writing

During the inspection, you stated that no QU oversight is performed for your suppliers and contract manufacturers, including packagers.

FDA Warning Letter · Safrel Pharmaceuticals LLC · 2026-08-18

In addition, no Quality Agreements have been established between your firm and the contracted laboratories to define roles, responsibilities, and oversight related to testing, data integrity, and compliance with cGMP requirements.

FDA 483 · Biomylz Private Limited · 2026-10-22 · View document

Questions to check against your procedures

  1. Are there written procedures that define the quality unit's responsibilities and the roles of its personnel?
  2. Is the person who tests a batch different from the person who approves its release?
  3. Have errors or missing details been found later in production records the quality unit had already approved?
  4. Has a batch been released on a retest result before the out-of-specification investigation was finished?
  5. When laboratory error is ruled out, do you obtain supporting documents such as the contract laboratory's investigation report?
  6. Do quality agreements define the quality unit's oversight and the split of roles for suppliers, contract manufacturers and contract laboratories?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-16.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.